RELAPSED AND REFRACTORY MM PROGRESSING ON 3L

Is SARCLISA + Pd appropriate for your RRMM patients?

Meet Anne — A patient with relapsed and refractory MM with disease progression on 3L treatment

Age
64 years old
Gender
Female
Time since MM diagnosis
5 years
R-ISS stage at diagnosis
Stage I

Initial treatment

  • Induction therapy was initiated with the bortezomib, thalidomide, dexamethasone (VTd) regimen
  • Anne achieved a CR and received ASCT

Disease progression

  • Anne’s disease progressed after 3 years
  • Anne completed re-induction therapy with the bortezomib, cyclophosphamide, dexamethasone (VCd) regimen. She achieved a VGPR and received a second ASCT
  • Upon progression one year later, Anne received a 3L combination of lenalidomide, dexamethasone (Rd)
  • After 1.5 years, at a regular clinic appointment her blood results revealed she had relapsed

Additional patient information

Cytogenetic risk
Standard
Bone marrow plasma cells
60%
Hg
9.5 g/dL
Renal function (CrCl)
75 mL/min/1.73 m2
Would Anne be a candidate for treatment with SARCLISA + Pd?

Anne would be eligible for treatment with SARCLISA + Pd1,2

Percentage of patients receiving SARCLISA + Pd in the ICARIA-MM trial with similar baseline characteristics2

You are now leaving the https://sarclisa.co.uk website.

By clicking on this link, you will be leaving this Sanofi hosted website, and, depending on the link, will be redirected to either another Sanofi website (for example, to view the Sanofi Privacy Policy) or an independent third-party website.
Sanofi has no control over the content or availability of third-party sites or resources that are linked to, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. The existence of a link between this website and any third party site or resource in no way implies that Sanofi in any way approves of the content of these sites or resources, or any use to which such content maybe put.

Please ensure that you read the legal and privacy policy sections of any website to which you link.

CONTINUE